William Wierda, PhD
Hematology & Oncology · Houston, TXNPI 1497848279
Payments from drug & device makers
Across 364 payments — averaging $161,178 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$52.3M
- Bristol Myers Squibb$2.6M
- Eli Lilly$2.1M
- Pharmacyclics LLC, An Abbvie Company$615K
- AbbVie$543K
- Acerta Pharma LLC$203K
- plus $383K from 15 others
Across 5 payments — averaging $5930.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$28K
- Bristol Myers Squibb$1K
- Pharmacyclics LLC, An Abbvie Company$41
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $52,262,950 |
| Bristol Myers Squibb | 12 | $2,606,572 |
| Eli Lilly | 49 | $2,055,410 |
| Pharmacyclics LLC, An Abbvie Company | 93 | $614,985 |
| AbbVie | 104 | $542,904 |
| Acerta Pharma LLC | 13 | $203,229 |
| Gilead(2 entities) | 10 | $137,358 |
| Genentech, Inc. | 20 | $103,804 |
| E.r. Squibb & Sons, L.L.C. | 1 | $70,457 |
| Novartis | 2 | $48,450 |
| Hikma Pharmaceuticals USA | 5 | $19,287 |
| F. Hoffmann-la Roche AG | 2 | $2,352 |
| Adaptive Biotechnologies Corporation | 3 | $241 |
| Lilly USA, LLC | 2 | $234 |
| Johnson & Johnson | 3 | $150 |
| Beigene USA, Inc. | 2 | $144 |
| Sobi, Inc | 2 | $133 |
| Astrazeneca UK Limited | 2 | $120 |
| Apellis Pharmaceuticals, Inc. | 1 | $104 |
| Genentech USA, Inc. | 3 | $73 |
| Pfizer | 1 | $13 |
How this compares
$58,668,969 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Houston
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- Koji SasakiHouston$39.2M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
- Philip ThompsonHouston$13.6M
- Naval DaverHouston$13.6M
- Ghayas IssaHouston$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.